The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.

A green light would have made Vyglxia the first and only FDA-approved treatment for spinocerebellar ataxia, a life-threatening neurodegenerative disease characterized by progressive loss of voluntary ...

Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch next. Click here to read more.

The investigational Bruton's tyrosine kinase inhibitor fenebrutinib reduced annualized relapse rates versus teriflunomide ...

The Oxford-Harrington Rare Disease Centre ('OHC') today announced the recipients of the 2025 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice.

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

Ten scientists selected for second annual award to pursue innovations in gene, RNA, small molecule and cell therapies to treat rare and ultra-rare diseases OXFORD, England ...

Biohaven stock cratered Wednesday after the FDA rejected the company's treatment for an inherited neurodegenerative disease.

Biohaven Ltd. narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending.

Texas Attorney General Ken Paxton is asking a judge to block the maker of Tylenol from paying out a $400 million quarterly shareholder dividend in anticipation of winning his lawsuit against Kenvue, ...